Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 236INDUSTRY 70NIH 41NETWORK 8OTHER_GOV 7UNKNOWN 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 1

Interventions

S 1 (combination) 12Capecitabine 11Paclitaxel 9Cisplatin 9apatinib 8Oxaliplatin 8pyrotinib 6nimotuzumab 6130-nm albumin-bound paclitaxel 6titanium silicide 5sintilimab 5camrelizumab 5anlotinib 5Etoposide 5Docetaxel 5Carboplatin 5Trastuzumab 4Radiotherapy, Intensity-Modulated 4Irinotecan 4Bevacizumab 4Albumin-Bound Paclitaxel 4nedaplatin 3Vinorelbine 3Temozolomide 3Tegafur 3Taxes 3Radiosurgery 3Gemcitabine 3Fluorouracil 3Epirubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × UNKNOWN × Erlotinib Hydrochloride × Clear all
NCT00600587 2013-06-25

Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)

GuangdongPPH

Phase 2 Completed
24 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00663689 2008-04-22

Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer

GuangdongPPH

Phase 2 Unknown
45 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡